Data Integration for Pharma: How Architecture Solves ALCOA+ Compliance

The Rising Cost of Pharma Data Integrity Failures

Data integrity is no longer a back-office concern. It is one of the most common reasons regulators issue observations during inspections.

The pattern repeats across the industry. An inspector asks a simple question: show me how this number got from the instrument to the submission. The answer involves three spreadsheets, two manual re-keys, and a folder of CSV exports nobody can fully account for. The data may well be correct. Proving it is the problem.

This is the heart of FDA data integrity expectations. It is not enough for a result to be right. You have to demonstrate, on demand, who recorded it, when, from what source, and that nobody altered it along the way.

Most pharma data lives in disconnected systems. LIMS, ELN, manufacturing execution, clinical databases, quality management, finance. Each holds part of the picture. Getting a complete view almost always means moving data between them. And every movement is a chance to break the chain.

The cost is not abstract. A data integrity finding can delay an approval, trigger a remediation programme, or stall a product launch by months. The engineering effort to fix integration after the fact dwarfs the cost of building it correctly from the start.

The root issue is architectural. When integrity depends on people remembering to log a change, it will fail eventually. The fix is to make integrity a property of the system, not a habit of the staff.

What ALCOA+ Actually Requires (And Why Current Approaches Fail)

ALCOA+ is the framework the FDA and EMA use to define what trustworthy data looks like. It started as ALCOA and grew four extra attributes. Today there are nine. Each one is a question your data must be able to answer.

Read that list as an engineer rather than an auditor. Most of these attributes are not about the data value at all. They are about the metadata around it: who, when, in what order, from where, and whether it has been touched since.

That is the part conventional integration throws away.

A typical data pipeline cares about getting the value from A to B. It does not, by default, preserve who entered it, the exact moment it was captured, or a tamper-evident record that it has not changed. So teams bolt those things on afterwards with logs, validation documents, and manual reconciliation. The attributes become paperwork instead of properties.

This is why so much effort goes into ALCOA+ data integrity and so little of it sticks. You cannot reliably retrofit attribution onto a record that was copied without it. The information was lost at the moment of transfer.

Why Excel and Manual Processes Break the ALCOA+ Chain

Spreadsheets are the default integration tool in pharma. They are familiar, flexible, and already on every desk. They are also where data integrity quietly goes to die.

Walk through one export-transform-import cycle, the classic spreadsheet shuffle, against the ALCOA+ attributes.

Someone exports results from the LIMS into a CSV. At that instant, attribution is gone. The export is a flat list of values. It no longer carries the system identity of the analyst who ran each test or the timestamp of capture. The new file says only that it was created today, by whoever clicked export.

They open it in Excel and reformat. Maybe they fix a unit, merge two columns, drop a few rows that look like noise. Each edit is a transformation. None of it is logged in any way an inspector would accept. Contemporaneity is broken: the timestamps now reflect the editing session, not the original work.

Then they import the cleaned file into the next system. The original record and the working copy have diverged. Which one is authoritative? In practice, nobody can say with confidence. Originality is gone.

Three attributes have already failed, and no one acted in bad faith. This is the ordinary friction of moving data by hand. Multiply it across dozens of these cycles a week and the gap between what you can prove and what actually happened grows wider with every transfer.

Validation does not close that gap. You can validate a spreadsheet template until the documentation is an inch thick, and the next analyst can still paste a value into the wrong cell. The control depends on human diligence. ALCOA+ asks for something diligence cannot supply: an unbroken, automatic record of provenance.

The problem is not Excel itself. It is using any uncontrolled, manual step as a bridge between systems. That is precisely where the hidden cost of data integration accumulates, not as licence fees, but as compliance risk and the labour of proving integrity after the fact.

Architecture-First Compliance: Governance Built In

The alternative is to stop treating integrity as something you check and start treating it as something the system guarantees.

This is the idea behind a governed data product. Instead of moving raw files between systems, you turn each source into a managed asset with a clear owner, a normalised schema, a documented API, and full lineage. The data stops being a loose file and becomes a product with rules attached.

Integrius Core is built around this model. When a source is connected, it becomes a data product with an owner and a defined schema. Every consumer reads through a governed API rather than receiving a copy. There is no orphaned export to reconcile, because there is no export.

The difference shows up directly against ALCOA+.

Attribution holds because every API call, connection test, and data access is recorded against an identity. Contemporaneity holds because actions are logged as they happen. Originality holds because consumers subscribe to the governed product rather than passing copies around.

The mechanism underneath is a tamper-evident audit trail. In Integrius, every action is written to an HMAC-chained, append-only log. A database trigger blocks updates and deletes outright, so the history cannot be quietly rewritten. An audit verify command walks the entire chain and exits with an error if a single row has been altered. That is the difference between claiming records are unchanged and being able to prove it during an inspection.

Lineage is captured on every transformation, and every mapping or schema change requires approval before it takes effect. A reviewer signs off, the change is recorded, and the trail is complete. Integrity becomes structural. It is a property of how the platform works, not a procedure people have to remember.

For regulated work, this also supports 21 CFR Part 11 electronic signatures. An approval can require re-authentication, a stated reason, and a cryptographic signature chained into the same audit log, so an electronic sign-off carries the same weight as a wet-ink one. If you want the wider rationale, data product governance explains why this structure beats bolt-on controls.

Drug Delivery Project Teams: The Use Case

Consider a representative example: a drug delivery project team preparing for a milestone review.

Their data is scattered, as it usually is. Around ten sources feed the picture. Formulation data in a SQL Server database. Stability results in a LIMS exposed over REST. Supplier records in Salesforce. Device telemetry arriving on Kafka. Batch records in PostgreSQL. Spreadsheets for the things that never found a home. Plus a few REST and event-log feeds from partner systems.

The conventional path is a formal integration project. Scope it, fund it, queue it behind other work, wait months for an engineering team to wire the sources together and validate the result. By the time it is ready, the review has happened and the questions have moved on.

With a governed platform, the shape of the work changes. Integrius ships with sixteen connectors covering REST, GraphQL, PostgreSQL, MySQL, SQL Server, MongoDB, Snowflake, BigQuery, Redshift, S3, Salesforce, Kafka, CSV, Excel, JSON, and event-log sources. Each source becomes a governed data product in minutes rather than weeks. The team queries a unified, governed view instead of stitching exports together by hand.

Crucially, the integrity attributes come along for free. Because every source is read through a governed API with its own audit trail, the lineage of every figure in that milestone review is recorded automatically. When someone asks where a stability number came from, the answer is one query, not an archaeology project across a shared drive. This is the same data foundation that determines whether an AI initiative succeeds or fails: governed inputs in, trustworthy outputs out.

Healthcare and Life Sciences: Fastest Growing Data Vertical

This is not a niche concern, and it is not shrinking. Healthcare and life sciences is the fastest-growing data vertical, expanding at roughly 18.91 percent CAGR through 2031, according to Mordor Intelligence.

That growth reflects real pressure. Clinical trials generate more data from more sources than ever: wearables, decentralised trial platforms, genomic sequencing, real-world evidence. Clinical trial data integration has become one of the hardest problems in the field, precisely because the sources multiply faster than the integration capacity to unify them.

More data does not mean more clarity. Without governance, it means more places for integrity to break and more surface area for an inspector to probe. The volume that is meant to accelerate development can just as easily slow it, if every new source adds another manual bridge to maintain and validate.

Strong pharma data governance is what turns volume into an asset rather than a liability. The organisations that handle this growth well will be the ones that treat each new source as a governed data product from day one, rather than another file to reconcile later. The discipline that protects integrity is the same discipline that lets a team actually use its data at scale.

Self-Hosted Deployment for Regulated Environments

There is a final requirement that rules out most modern tooling for pharma. The data cannot leave the building.

Formulations, clinical results, patient data, and manufacturing records are among the most sensitive assets a life sciences company holds. Routing them through a third-party SaaS platform, with its own sub-processors and outbound connections, is a non-starter for many quality and security teams. The compliance burden of validating someone else's cloud often outweighs any convenience it offers.

Integrius is self-hosted by design. It runs inside the customer's own infrastructure via Docker or Helm. It makes zero outbound calls at runtime, supports fully air-gapped deployment, and relies on no SaaS sub-processors. There is no phone-home. The data never leaves the network, which means the integration layer sits inside the same validated, controlled environment as the systems it connects. The wider case for this model is set out in why self-hosted data governance is winning.

That deployment model pays off directly at inspection time. Because every API call, connection test, and data access is recorded in a tamper-evident audit trail held entirely within your own infrastructure, inspection readiness stops being a scramble. The evidence already exists, in order, and provably unaltered. You are not assembling a story after the fact. You are showing a record that was complete the moment it was created.

This is where architecture and compliance finally align. ALCOA+ asks for attributable, contemporaneous, original, and enduring records. A governed, self-hosted data layer produces exactly that as a by-product of normal operation, rather than as a separate quality effort layered on top.

See how Integrius makes ALCOA+ compliance structural. Built for pharma. Talk to us.